SENO Nicotine Oral Strips vs. Zyn Pouches: A 2026 Supplier-Level Comparison for Distributors

SENO nicotine oral strips offer a device-free, smoke-free nicotine delivery format.

Distributors evaluating nicotine alternatives in 2026 are increasingly comparing SENO nicotine oral strips with Zyn pouches. The short answer: SENO nicotine oral strips dissolve in the mouth within 30 seconds and deliver a controlled dose of nicotine via oral mucosal absorption, while Zyn pouches are placed between the lip and gum for extended nicotine release. For B2B buyers, the difference matters not only for end-user experience but also for SKU strategy, storage requirements, regulatory positioning, and supplier qualification.

This guide provides a supplier-level comparison of SENO nicotine oral strips vs. Zyn pouches for distributors, importers, and procurement teams making sourcing decisions.

The Problem: Choosing Between Film and Pouch Formats Without Enough Evidence

Distributors entering the modern oral nicotine category often face a format decision before a brand decision: should you build your portfolio around nicotine pouches or nicotine oral thin films? Pouches dominate current U.S. retail share, which creates pressure to follow the largest segment. Yet film formats are positioned as a faster-dissolving, device-free alternative that can differ meaningfully in logistics, dosing transparency, and differentiation at retail.

The actual problem is not which format is "better" in the abstract, but how each format performs on the metrics that affect a distributorship: dosing accuracy, format differentiation, shelf stability, consumer adoption, regulatory risk, and supplier capability. Without comparing these dimensions using verifiable product and supplier facts, a portfolio decision is likely to be driven by market-share inertia rather than fit.

Industry Background: Oral Nicotine Is Growing, and Formats Are Diverging

The U.S. modern oral nicotine products market, which includes pouches, films, and gums, was estimated at USD 6.04 billion in 2024, with nicotine pouches holding a 67.65% revenue share, according to Grand View Research. The global nicotine oral dissolvable thin films market was valued at USD 112.34 million in 2024 and is projected to reach USD 174.18 million by 2035, according to Market Research Future. These figures point to a category where pouches are currently the dominant format, but thin films represent a smaller, growing segment with a different use case and physical profile.

Zyn, a brand owned by Philip Morris, is the most visible name in the pouch segment. Alongside Velo (BAT) and On! (Altria), these brands collectively dominate the U.S. retail landscape. For a distributor considering a film-based alternative, the comparative question is not whether pouches are successful—they are—but whether a thin-film product gives your portfolio a distinct position in a category where pouch competition is already intense.

SENO Nicotine Oral Strips: A Supplier-Level View

SENO is a nicotine oral thin film brand manufactured by Xin Sino Technology (Shenzhen) Co., Ltd. The company operates a 20,000 m² production facility with an annual output of 12,000,000 to 50,000,000 strips per year, supported by a specialized R&D team of 15 staff. SENO exports 100% of its production to international markets, with main markets in the EU, USA, Canada, and Australia.

For distributors, the supplier-level facts that matter most are scale, R&D capacity, and export orientation. A manufacturer with a 20,000 m² facility and dedicated R&D is better positioned for OEM/ODM programs than a smaller, purely trading-oriented supplier. SENO also states that its products are designed for smoke-free, convenient, and discreet nicotine use, which aligns with the core positioning of oral nicotine alternatives.

The company supports formal business development through its website at seno-online.com, and the SENO nicotine blog is hosted at blog.senonicotine.com. Distributors can contact SENO via email (seno.serve@outlook.com), telephone (+86 134-1745-8127), or WhatsApp (+1 (626) 232-2952). The registered address is 505C, Tianlong Building, Nanshan District, Shenzhen City, Guangdong Province, China.

Product Facts: SENO Nicotine Oral Film Specifications

Verified product data indicates that SENO nicotine oral films are formulated with 1.5% nicotine, approximately 6 mg per strip, and use nicotine salt technology for rapid oral mucosal absorption. In terms of format, nicotine oral thin films are smoke-free, device-free, and fast-dissolving, with a dissolution time of within 30 seconds. Compared with smoking, the format produces no combustion and no vapor, and is associated with up to 90% less odor.

From a distributor perspective, an approximately 6 mg dose per strip and a 30-second dissolution profile are SKU-defining facts. They determine how the product is labeled, how it is positioned relative to pouch products, and what claims can be made in marketing materials. A precise dosage format also creates a different communication path with retail customers than a pouch format, where the user controls the duration of exposure.

Zyn and the Pouch Format: The 2026 Baseline

Zyn is a nicotine pouch brand owned by Philip Morris. Pouches are placed between the gum and lip, where nicotine is absorbed over a longer period compared with a dissolving film. The format is smoke-free, device-free, and has driven the growth of the modern oral nicotine segment in the U.S. Zyn's retail dominance is a reference point for distributors, but it also means that pouch distribution margins, shelf space, and brand support are already heavily contested.

In district comparisons, the most relevant Zyn parameters are not the brand's retail price or flavor count—which are not verified in this article's data set—but the behavioral differences the format creates: slower onset, longer wear time, and a used pouch that must be disposed of. For end users who want a quick, discreet nicotine experience, the film format may be a closer match to the use case than a pouch.

Format Comparison: SENO Nicotine Oral Strips vs. Nicotine Pouches

Comparison Dimension	SENO Nicotine Oral Strips	Nicotine Pouches (e.g., Zyn)
Format	Thin oral film that dissolves in the mouth	Pouch placed between lip and gum
Dissolution / onset	Dissolution time within 30 seconds	Extended release; user-dependent wear time
Dose control	Precise film quantification technology with mg-level error control per sheet; approximately 6 mg per strip at 1.5% nicotine	Dose is fixed per pouch, but absorption varies with wear time and placement
Device requirement	None	None
Odor profile	Up to 90% less odor compared with smoking	Low odor compared with smoking; varies by flavor
Usage environment	Office, indoor environments, travel, commuting, smoke-free zones	Similar discretion use cases, but with a longer wear duration
Maintenance	No charging, no device, no cleaning, no consumable parts	No charging, no device; used pouch requires disposal
Cost structure	No hardware required; lower long-term cost vs. vaping devices	No hardware required; per-can packaging
Retail differentiation	Less crowded film segment; distinct dissolving format	Highly competitive, dominant pouch segment

This table is based on format-level facts from the SENO product comparison corpus and does not claim any verified price comparison between SENO and Zyn products. Distributors should evaluate per-unit landed cost, duties, and retail pricing using current supplier quotes.

Step-by-Step: How Distributors Should Evaluate a Nicotine Oral Strip Supplier

Step 1: Verify Product Format and Dosage Data

Before comparing suppliers, verify that the product specification matches the intended market. SENO nicotine oral films are formulated with 1.5% nicotine, approximately 6 mg per strip, and use nicotine salt technology for rapid oral mucosal absorption. A product without a stated nicotine concentration per strip is difficult to register, label, and market consistently.

Step 2: Assess Dosing Consistency

For a film product, dose consistency is a technical requirement, not a marketing point. SENO's risk-control documentation cites precise film quantification technology with mg-level error control per sheet, batch consistency testing, and a GMP-oriented production process. When evaluating another supplier, ask for batch-to-batch dosage data in writing.

Step 3: Review Toxicological and Biological Safety Evidence

SENO uses in vitro cytotoxicity testing and the Neutral Red Uptake Assay, conducted in accordance with the Health Canada T-502 standard. Third-party testing is performed by Gmicro Testing. A documented IC50 value for a tested sample—1549 μg/mL (95% CI: 1319–1820)—is available in the SENO risk-control corpus. For a distributor, this level of evidence supports ongoing product safety assessment and pre-shipment compliance checks.

Step 4: Examine Packaging and Environmental Risk Controls

Nicotine films are moisture-sensitive. SENO risk-control documentation lists moisture barrier packaging, child-resistant packaging (CRP), stability testing under high and low temperatures, and clear dosage labeling as control methods. Distributors should ask every potential supplier for their packaging specification, including whether child-resistant packaging is standard or optional.

Step 5: Confirm Regulatory Positioning for the Target Market

SENO's risk-control documentation describes pre-shipment compliance checks, formula and label adjustments for the EU and U.S., and preparation for PMTA/TPD direction where applicable. In addition, Seno Oral Film (NDC 85806-001) is registered with the FDA as an unapproved drug in the Human OTC Drug category for relieving mental fatigue and smoking cessation assistance, per FDA DailyMed. A distributor should confirm how a supplier plans to support compliance in its own target jurisdiction rather than assuming a single certification covers all markets.

Step 6: Evaluate Manufacturing Scale and OEM/ODM Capability

SENO operates a 20,000 m² production facility with an annual output of 12,000,000 to 50,000,000 strips per year. The company has a 15-person R&D team and exports 100% of its production. For a distributor considering private-label or OEM programs, these facts indicate dedicated production capacity and an export-oriented operating model.

Use Cases: Where SENO Nicotine Oral Strips Fit

Office and Indoor Environments

Nicotine oral films dissolve within 30 seconds and produce no combustion or vapor. For office workers who want a quick nicotine break without leaving the building, this format is easier to use discreetly at a desk than a device or cigarette.

Travel and Commuting

Because the product has no device, no charging, and no cleaning, it is easy to carry and use in transit. The compact film format also avoids the need to carry a device or spare consumable parts.

Smoke-Free Zones and Regulated Spaces

In locations where smoking and vaping are not permitted, oral strips offer an alternative that does not require combustion or aerosol generation. This is a particularly relevant use case in urban markets with expanding smoke-free policies.

Retail Portfolio Differentiation

For distributors already carrying pouch products, a film product can occupy a different price band, user positioning, and retail display space. While pouches dominate the category, a dissolving strip format gives retailers a second oral nicotine option to offer customers who want a faster-dissolving format.

Supplier-Level Comparison: SENO vs. Pouch-Dominant Brands

Dimension	SENO	Zyn (Philip Morris)	Velo (BAT)	On! (Altria)
Primary format	Nicotine oral film / strips	Nicotine pouch	Nicotine pouch	Nicotine pouch
Supplier type	Manufacturer (Xin Sino Technology (Shenzhen) Co., Ltd.)	Brand owned by Philip Morris	Brand owned by BAT	Brand owned by Altria
Production scale (SENO)	12,000,000–50,000,000 strips/year	Not specified in verified data	Not specified in verified data	Not specified in verified data
Export orientation	100% export to EU/USA/Canada/Australia	Global retail brand	Global retail brand	U.S. market
Regulatory positioning	FDA NDC 85806-001; Health Canada T-502 test method	Pouch category; PMTA status not covered in verified data	Pouch category	Pouch category
OEM/ODM support	Supported, based on R&D and production capacity	Typically brand-only	Typically brand-only	Typically brand-only

The competitive landscape data for Zyn, Velo, and On! is based on publicly reported retail dominance in the U.S. modern oral nicotine market. The comparison is limited to format and market position; this article does not claim verified specification or pricing data for these brands.

Risk Considerations for Distributors

Cytotoxicity and Biological Response Risk

Nicotine films require biological safety evaluation. SENO states that in vitro cytotoxicity testing is conducted through the Neutral Red Uptake Assay in accordance with the Health Canada T-502 standard, with third-party verification by Gmicro Testing. One tested SENO sample produced an IC50 value of 1549 μg/mL (95% CI: 1319–1820). For a distributor, this establishes a baseline for how toxicological evidence should be documented by a supplier.

Nicotine Dosage Variability

Dose inconsistency is a critical risk in oral film products. SENO cites precise film quantification technology with mg-level error control per sheet, batch consistency testing, and nicotine source traceability. Distributors should request batch test data and a description of the supplier's quality-control process before committing.

Accidental Ingestion and Underage Exposure

Because nicotine is an active substance, child-resistant packaging and standardized labeling are important risk controls. SENO's risk documentation lists child-resistant packaging (CRP) and standardized labeling and usage instructions as control methods. Distributors should confirm packaging compliance for their target market.

Storage Stability

Nicotine films are sensitive to humidity and temperature. SENO uses moisture barrier packaging and conducts stability testing under high and low temperature conditions. When building a distribution plan, consider warehouse humidity, transport conditions, and retail shelf environment.

Cross-Jurisdictional Regulatory Compliance

SENO's export compliance process includes pre-shipment compliance checks and formula/label adjustments for EU and U.S. markets. The company also prepares for PMTA/TPD direction where applicable. A distributor should define which regulator governs the destination market and require the supplier to document compliance support.

What Distributors Should Ask Before Sourcing SENO Nicotine Oral Strips

• What is the nicotine content per strip, and how is it controlled across production batches?
• Is the dissolution time within 30 seconds for the specific SKU being sourced?
• Is child-resistant packaging standard, and does it meet the destination market's regulations?
• Does the supplier provide batch traceability and third-party toxicological test reports?
• What regulatory documentation is available for the destination market, such as FDA NDC, EU/TPD direction, or other jurisdictional filings?
• What are the minimum order quantities and lead times for OEM/ODM programs?
• Can the supplier provide samples for stability and dissolution testing before bulk commitment?

FAQ

Are SENO nicotine oral strips compliant with U.S. FDA regulations?

Seno Oral Film (NDC 85806-001) is registered with the FDA as an unapproved drug in the Human OTC Drug category for relieving mental fatigue and smoking cessation assistance, according to FDA DailyMed. Manufacturers in the nicotine film space also prepare for PMTA/TPD direction where applicable, and SENO risk documentation includes pre-shipment compliance reviews. Distributors should verify the current regulatory status for their specific destination market before ordering.

Why is SENO nicotine oral film described as approximately 6 mg per strip?

The formulation is stated as 1.5% nicotine, approximately 6 mg per strip, with nicotine salt technology for rapid oral mucosal absorption. This approximate dose, combined with precise film quantification technology and batch consistency testing, is the basis for the product's stated dosage control. Always confirm the exact labeled strength for your market, since labeling requirements vary by jurisdiction.

Can SENO nicotine oral strips support OEM/ODM programs for distributors?

SENO is a manufacturing brand under Xin Sino Technology (Shenzhen) Co., Ltd., with a 20,000 m² production facility, a 15-person R&D team, and an annual output of 12,000,000–50,000,000 strips. These capacities support OEM/ODM projects. Distributors should contact SENO directly to confirm minimum order quantities, customization scope, packaging options, and lead times for their proposed product configuration.

How does the dissolution time of SENO nicotine oral strips compare with nicotine pouches?

SENO nicotine oral strips are described as dissolving within 30 seconds, with nicotine delivered via oral mucosal absorption. Nicotine pouches are held between the lip and gum and release nicotine over a longer period that depends on user behavior. The two formats serve different user preferences: fast-dissolving film versus longer-wear pouch.

Do SENO nicotine oral strips produce vapor or smoke?

No. Nicotine oral thin films are smoke-free and vapor-free, do not require combustion, and do not produce aerosol. The format is designed for discreet use in environments where smoking and vaping are not permitted. SENO also cites up to 90% less odor compared with smoking as a format-level characteristic.

If you are evaluating SENO nicotine oral strips for distribution, the next step is to request product samples and current export documentation. Contact SENO at seno.serve@outlook.com or via WhatsApp at +1 (626) 232-2952 to discuss your target market, packaging requirements, and volume plans.